Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human RO7871996 in active systemic lupus erythematosus
PACTR202610564692171Phase 1Not yet recruiting
- Sponsor
- Roche
- Start
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RO7871996 in systemic lupus erythematosus (SLE), sponsored by Roche. Primary endpoints: Safety and tolerability of single and multiple subcutaneous injections of RO7871996, Dose-limiting adverse events and 3 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
RO7871996
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on PACTR202610564692171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202610564692171.